Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Core Insights - Aclaris Therapeutics has completed patient enrollment in a Phase 2 trial for bosakitug (ATI-045) targeting moderate-to-severe atopic dermatitis, with top line results expected in Q4 2026 [2][3] Company Overview - Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for immuno-inflammatory diseases [8] - The company has a robust R&D pipeline aimed at addressing unmet medical needs in patients with conditions lacking satisfactory treatment options [8] Product Details - Bosakitug is a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody designed to inhibit TSLP, which plays a significant role in inflammatory responses [4] - The drug has demonstrated a strong safety profile and efficacy in previous trials, with 94% of participants achieving EASI-75 scores and 88% showing clear or nearly clear skin [4] Clinical Trial Information - The Phase 2 trial involves 109 patients and will assess primary and secondary efficacy endpoints, including changes in the Eczema Area and Severity Index (EASI) and safety measures [3] - The trial's primary endpoint is the percent change from baseline in EASI at week 24, with secondary endpoints including various response measures and pharmacokinetic assessments [3] Disease Context - Atopic dermatitis (AD) affects approximately 10 million children and 17 million adults in the U.S., with over 200 million people affected globally [6] - The condition significantly impacts quality of life, with a notable prevalence of moderate to severe symptoms among affected individuals [6] Mechanism of Action - TSLP is a key regulator of the Type 2 immune response and is involved in various allergic and inflammatory diseases, making it a relevant therapeutic target [5]